eis Promoter C14G and C15G Mutations Do Not Confer Kanamycin Resistance in Mycobacterium tuberculosis

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7522-7523. doi: 10.1128/AAC.01775-16. Print 2016 Dec.

Abstract

We studied the significance of particular eis mutations on Mycobacterium tuberculosis drug resistance using a specialized transduction strategy. Recombinant strains harboring eis promoter mutations C14T, C12T, and G10A exhibited kanamycin resistance with MICs of 40, 10, and 20 μg/ml, respectively, while recombinant strains harboring C14G and C15G mutations were kanamycin susceptible (MIC, 2.5 to 5 μg/ml). Each of the eis mutants tested remained amikacin susceptible (MIC, 0.5 to 4 μg/ml). The identification of specific eis mutations is needed for accurate genotypic susceptibility testing for kanamycin.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acetyltransferases
  • Amikacin / pharmacology
  • Antigens, Bacterial / genetics*
  • Antigens, Bacterial / metabolism
  • Antitubercular Agents / pharmacology*
  • Bacterial Proteins / genetics*
  • Bacterial Proteins / metabolism
  • Gene Expression
  • Genotype
  • Kanamycin / pharmacology*
  • Kanamycin Resistance / genetics
  • Mutation*
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / genetics
  • Mycobacterium tuberculosis / growth & development
  • Promoter Regions, Genetic
  • Transduction, Genetic

Substances

  • Antigens, Bacterial
  • Antitubercular Agents
  • Bacterial Proteins
  • Kanamycin
  • Amikacin
  • Acetyltransferases
  • Eis protein, Mycobacterium tuberculosis